Digumarti R, Sinha S, Nirni SS, Patil SG, Pedapenki RM. Indian J Cancer. 2014 Apr-Jun;51(2):180-3. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Meka P, Annamaneni S, Digumarthi R, Sinha S, Satti V. Tumour Biol. 2015 May 10. [Epub ahead of print]. Influence of BCL2-938C >A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India
Cingeetham A1, Vuree S, Jiwatani S, Kagita S, Dunna NR, Meka PB, Gorre M, Annamaneni S, Digumarti R, Sinha S, Satti V. Asian Pac J Cancer Prev. 2015;16(7):2707-12. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development
Cingeetham A, Vuree S, Dunna NR, Gorre M, Nanchari SR, Edathara PM, Mekkaw P, Annamaneni S, Digumarthi RR, Sinha S, Satti V.Tumour Biol. 2014 Sep;35(9):8813-22. Association of caspase9 promoter polymorphisms with the susceptibility of AML in south Indian subjects.
Chiranjeevi P, Spurthi KM, Rani NS, Kumar GR, Aiyengar TM, Saraswati M, Srilatha G, Kumar GK, Sinha S, Kumari CS, Reddy BN, Vishnupriya S, Rani HS. Tumour Biol. 2013 Dec 20. [Epub ahead of print]. Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer.
Anuradha V, Anand BB, Suresh AV, Sinha S, Babu SC, Suresh K.Indian J Med Paediatr Oncol. 2013 Jan;34(1):11-5. Palliative chemotherapy in head and neck squamous cell cancer â€“ What is best in Indian population? A time without symptoms, treatment toxicity score based study.
Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Sudha Sinha and her staff know how they are doing and how they can improve their services.
How was your experience with Dr. Sudha Sinha?
Help other patients, and let the doctor know how she's doing